October 21, 2015 : Latest GLP-1 Receptor Agonists News, Oct. 22, 2015

EXCLUSIVE INTERVIEW — Candid Video Interviews with Top Practitioners

Dr. Paresh Dandona, Part 1: GLP-1 Receptor Agonists as Adjunctive Treatment in Type 1 Diabetes

DISASTERS AVERTED — Near Miss Case Studies

Can Smaller Forks Help Diabetes Patients?

Latest News

 Diabetes Medication May Be Used In Treating Alcohol Dependence

Early-on in DPP-4 Inhibitor drug development there was a product ready to go before Januvia. The pills were in the bottle, the booth was ready to go at ADA and then the drug was withdrawn from the market, because of reports of skin lesions. The word on the street indicated that maybe these enzymatic inhibitors had effects other than just increasing native GLP-1 levels.

Now it appears that GLP-1 analogs may do more than we ever thought. In fact a recent study, published in the Journal Addiction, makes a case for using Liraglutide for alcohol dependence and we have the compelling information on why this may become a new indication for the molecule to go along with diabetes (Victoza) and weight loss (Saxenda).

Dr Paresh Dandona shares his insights on the use of GLP-1 therapy in Type 1 diabetes and why we have seen an uptick in the concurrent use.

Your partner in diabetes care,
Dave Joffe
Editor-in-chief

Dr. Paresh Dandona, Professor of Medicine and Chief of the Division of Endocrinology, Diabetes and Metabolism at the University of Buffalo, The State University of New York, joins Associate Medical Editor Joy Pape in a discussion at the 2015 ADA Sessions in Boston regarding highlights of his presentation, “GLP-1 Receptor Agonists as Adjunctive Treatment in Type 1 Diabetes.”

Patient, female, 54 years of age, type 2 diabetes and obesity, told me she thought her weight and subsequent type 2 diabetes related to overeating, especially large portions. She is being seen by a behavior therapist for her eating disorder. I started her on a GLP-1. Even at starting dose, she reported feeling more satiated, but still overeating. The dose was increased…

Liraglutide use led to less alcohol intake and suppressed dopamine effects in rodents.